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ABSTRACT
Delayed immune reconstitution is 1 of the major contributions to the morbidity and mortality after haploident-
ical transplantation. Patients with a slow recovery of the innate and especially of the adaptive immune system are
at high risk for severe and often lethal infections. The reason for delayed immune reconstitution after haploi-
dentical transplantation include the T cell depletion (TCD) of the graft, the thymic dysfunction induced by
pretransplant chemotherapies and by the conditioning regimens, and the occurrence of graft-versus-host
disease (GVHD) and its treatment. The detailed analysis, understanding, andmanipulation of the reconstitution
of the cellular immune system will be of utmost importance to overcome the posttransplant immunodefcient
status, and should result in a reduced risk of severe and overwhelming infections and hopefully also to a reduced
risk of relapse through better immunological control of residual malignant cells.
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NK cellsRECONSTITUTION OF T CELLS
Various methods of T cell depletion (TCD) have
been used in allogeneic stem transplantation [1-3].
Although the degree of TCD varied among these
methods, they were all associated with a delayed recon-
stitution of the T-lymphocytes, resulting in severe
and often lethal infectious complications in the post-
transplant course.
Other methods use combined in vitro and in vivo
TCD stategies without or with subsequent adoptive
transfer of nonalloreactive donor cells [4,5].
More recently developed methods, such as CD341
positive selection, resulted in a high degree of TCD
(5 log) and enabled the transplantation and tolerance
induction across the HLA barrier [6,7], but were also as-
sociated with a high rate of infectious complications [8].
In our initial work, we have widely used the posi-
tive selection of haploidentical granulocyte–colony-
stimulating factor (G-CSF)-mobilized peripheral
CD341 stem cells as an indirect method of TCD in
pediatric patients [9]. Using this approach, we were
able to demonstrate in clinical trials that(1)
1. Haploidentical transplantation with CD341
positively selected stem cells is possible without
significant graft-versus-host disease (GVHD)
[9] and is a reasonable alternative for children
with malignant or nonmalignant diseases who
do not have an HLA-matched related or unre-
lated donor [10].
2. The immune reconstitution after transplanta-
tion with CD341 selected stem cells is very de-
layed and associated with a high risk of severe
and often lethal viral or fungal infections [11].
(2)
3. Alloreactive NK cells play a major role in the
protection from posttransplant relapse [12,13]
and might support the engraftment and protect
from GVHD [14].
Initially, we have used myeloablative preparative
regimen with the CD341 positive selection to ensure
engraftment [9]. However, we have experienced
a high treatment-related mortality (TRM) in associa-
tion with myelablative conditioning regimens in the59
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immune reconstitution. From these initial experiences
with CD341 positive selection, we have concluded that
an ideal graft should not only be composed of highly
purified CD341 stem cells, but should also contain
NK cells from a preferentially NK-alloreactive donor.
Therefore, we have established a TCD [15] and a TCD
and B cell depletion method [16] for haploidentical
transplantations based on the Magnetic-activated cell
sorter that retains large numbers of NK cells and other
cells. The additional B cell depletion was introduced to
avoid donor-derived posttransplant EBV-associated
lymphoproliferative disease (Figure 1).
Based on experimental data in animal models that
NK cells might facilitate engraftment [14], we hypoth-
esized that NK-cell enriched CD3-depleted stem cells
should support the engraftment of haploidentical stem
cells and initiated clinical trials with CD3-depleted
stem cells at St. Jude Children’s Research Hospital
Memphis using either a myeloablative total bodyirradiation (TBI)-containing preparative regimen or
reduced intensity conditioning (RIC) approach. For
in vivo B cell depletion, patients received a single
dose of the anti-CD20 antibody Rituxan prior to
stem cell infusion.
To assess the immune reconstitution, lymphocyte
subsets were analyzed by flow cytometry. In addition,
the thymic function was assessed by measuring T cell
receptor excision circles (TRECs) as a measure for
the de novo generation of thymocytes [17] and the T
cell receptor beta repertoire was assayed by V-beta
spectratyping.
The comparative analyis of the immune reconsti-
tution after a myeloablative TBI-containing regimen
(TBI 12 Gy, Thiotepa 10 mg/kg, Cytoxan 120 mg/
kg, ATG, and anti-CD3) [18] and an RIC regimen
(Fludarabine 200 mg/m2, Thiotepa 10 mg/kg, Mel-
phalan 120 mg/m2, and anti-CD3) [19] showed an
accelerated immune reconstitution of the CD41 T-
helper lymphocytes and a rapid increase of CD561Figure 1. The fundamental difference between CD341 positive selected (left panel) and CD3/C19-depleted (right panel) mobilized peripheral
stem cells from haploidentical donors is shown. Although CD341 positive selection results in a homogenous population of highly purified
CD341 stem cells, CD3/C19 depletion results only in a low enrichment of CD341 cells, but retains large numbers of CD561NK cells and other
myeloid cells.
Cellular Immune Reconstitution after Haploidentical Transplantation in Children 61NK cells in the patients who received the RIC regi-
men. In addition, patients after RIC conditioning
had a much faster thymic recovery as documented by
a rapid increase of TREC and a faster reconstitution
of the TCR, as measured by the V-beta spectratypingscores. The rapid immune reconstitution of the TCR
in the RIC patients was associated with less reactiva-
tion of CMV and adenovirus (ADV) and in case of
reactivation with much lower copy numbers [20]. In
Figure 2, this comparative analyis is shown.Figure 2. Comparative analyis of CD41 T-helper cells and CD561 NK cells after transplantion with haploidentical CD3-depleted PBSCs after
TBI-containing myeloablative regimen (circle) or RIC regimens (triangle) (upper panel). In the middle panel, the recovery of the TRECs and the
V-beta spectratyping score is depicted. In the lower panel, the copy numbers as determined by real-time PCR in patients with reactivation of
cytomegalovirus (CMV) or adenovirus (ADV) is shown.
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approach is associated with a delayed de novo thymic
generation of T-lymphocytes and a delayed establish-
ment of the T cell receptor repertoire, we decided to
abandon myeloablative conditioning regimens in pa-
tients undergoing haploidentical transplantations and
initiated a clinical protocol using the IC approach for
patients with malignant and nonmalignant diseases
[21]. The conditioning regimen includes Fludarabine
(160 mg/m2), Thiotepa (10 mg/kg), and Melphalan
(140 mg/m2) and the anti-CD3 antibody OKT-3 (27
patients). In 10 patients with refractory malignant
disease, we used clofarabine (200 mg/m2) instead of
fludarabine without any major toxicitiy (unpublished
data).
ADOPTIVE TRANSFER OF VIRUS-SPECIFIC T CELLS
For patients who do not develop a specific T cell
response to CMV or ADV and are therefore at high
risk for severe infection, we have developed at the
Children’s University Hospital Tuebingen a rapid
and GMP-conform and approved method for the in vi-
tro isolation of CMV- or ADV-specific donor T cells
for posttransplant adoptive transfer using the Inter-
feron-gamma secretion method [22]. Briefly, donor
mononuclear cells are incubated overnight with theviral antigen. The interferon-gamma secreting T cells,
composed of CD41 and CD81 subsets, are then
isolated using the interferon-gamma capture method.
In Figure 3A, the purification steps are depicted. In
Figure 3B, the in vivo expansion of ADV-specific T
cells in patients with posttransplant ADV reactivation
and the reduction of the ADV copy numbers or the
clearance is show.
In a retrospective comparative analysis of the inci-
dence of lethal viral infections after haploidentical
transplantation after either CD341 selection and mye-
loablative regimens or CD3/CD19-depleted stem cells
and RIC regimens in patients transplanted at the Chil-
dren’s University Hospital in Tuebingen, we have seen
a major difference between the 2 approaches. Although
almost 20% of the patients died from a viral infections
after CD341 selection and myeloablation, none of the
37 patients who were transplanted to date (June 2007)
with CD3/C19-depleted stem cells after RIC condi-
tioning died from this complication. It is noteworthy
that there was no death in this group from any in-
fection. In Figure 4, the result of this comparative
retrospective analysis is shown. In addition, the
TRM after RIC conditioning was very low (1 out of
37), whereas the TRM rate was up to 35% in the pa-
tients who received myeloablation and CD341 posi-
tively selected stem cells [23].Figure 3. The in vitro purification steps of ADV-specific donor T cells are shown. Mononuclear cells from the haploidentical stem cell donor
were isolated and incubated overnight with viral antigen. After stimulation, 0.7% of the CD31 T cells were found to secrete interferon-gamma
and thus specific for ADV (A, left panel). These ADV-specific T cells are composed of CD41 and CD81T cells (A, middle panel). After isolation
using the interferon-gamma capture assay, the interferon-gamma secreting CD31 T cells are highly enriched and ready for infusion into the
patient (C, right panel). In (B), the expansion of ADV-specific T cells in 5 patients with posttransplant ADV reactivation (left panel) and the
concomitant decrease of the ADV copy numbers or the complete clearance (right panel) is shown.
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Alloreactive natural killer (NK) cells might play
a major role not only in the prevention of infections,
but also in the prevention of disease recurrence in pa-
tients with malignant diseases, especially in the context
of RIC regimens. Therefore, a major focus of our work
is directed on the analysis of the reconstitution of NK
cells and especially of the killer inhibitory and activa-
tory receptor (KIR and KAR) repertoire after haploi-
dentical transplantation. We have shown previously
that, in the context of CD341 positive selection and
myeloablation, the alloreactive status between donor
and recipient is predictive for the risk of relapse
[12,13]. Using monoclonal antibodies against KIRs,
the KIR repertoire of the donors and of the patients
can be followed after transplantation by flow cytome-
try and can also be used to identify an NK-alloreactive
donors [13]. In most of the patients, the KIR repertoire
of the donor starts to reestablish after approximately 3
months posttransplant, whereas during the first
months posttransplant, NK cells without KIR expres-
sion or with a skewed repertoire are the predominant
cell population [11].
Besides the KIR repertoire, the number of inhibi-
tory HLA class I molecules on leukemic targets and
Figure 4. Comparative retrospective analysis of the cumulative inci-
dence of lethal viral infections after myeloablative conditioning reg-
imens and CD341 positive selection and after RIC regimen and
CD3/CD19 depletion. In the myelablative group (upper panel), al-
most 20% of the patients died from a lethal infection. Half of these
patients had a lethal ADV infection, whereas no death from ADV or
any other viral, bacterial, or fungal infection was seen in the RIC
group (lower panel).the functional activity of the NK cells (NK activity)
also play a role in NK-mediated cytotoxicity against
blasts [24]. We are therefore monitoring the NK activ-
ity of the all patients using the standard NK cytotoxic-
ity assay against the standard target cell line K 562 and
the number of surface inhibitory or activatory HLA-
antigens on the patients’ blasts.
ANALYSIS OF CHIMERISM AND MINIMAL RESIDUAL
DISEASE
It has been shown that the establishment and main-
tenance of a complete donor chimerism is associatesd
with a lower risk of relapse, and that decreasing donor
chimerism might be a herald for relapse [25]. Although
conventional assays are based on DNA analysis, the
haploidentical situation between donor and recipients
allows the analysis of chimerism via the different ex-
pression of HLA antigens on the cell surface of the he-
matopoietic cells. Therefore, we have established an
easy and rapid method for the analysis of chimerism
based on flow cytometry [26]. Because of the HLA
mismatch, suitable anti-HLA antibodies can be identi-
fied in.80% of donor/recipients. Because most of the
antibodies against lymphocyte surface antigen are
available in conjugation with various fluorescent
dyes, the method allows the exact analyis of donor-
and recipient-derived cells and their subsets. With 1
mL of whole blood, an extensive analysis of all HLA-
expressing cells and their subsets is possible. Because
of the high sensitivity of the method, decreases of do-
nor chimerism can be recognized very early.
In Figure 5A and B, a representative flowcytomet-
ric analysis of chimerism posttransplant is shown. In
this example, the donor is HLA-A2/28 positive,
whereas the recipient is HLA-A2/28 negative. As can
be seen in the flowcytmetric analysis, all CD561 NK
cells (A) and CD31 T-cells (B) are positive for HLA-
A2/28, and thus are donor-derived.
In addition, the method can be used for the early
detection of minimal residual disease (MRD) postrans-
plant, similar to the already described flowcytometric
MRD detection methods for residual leukemic blasts
[27]. Because the malignant cells are recipient derived,
a gate can be set on the cells expressing the patients
HLA antigens, and the leukemic phenotype of these
cells can be determined. This approach further
increases the sensitivity of the method for early
MRD detection. In Figure 5C and D, an example is
shown. In this patient, peripheral recipient-derived
CD45dim1 positive cells were seen, whereas all do-
nor-derived hematopoietic cells were CD45bright1
(C). Additional staining showed that all these recipient
derived CD45dim1 cells had the leukemic phenotype
(CD341) (D) of the patient’s blasts prior to transplant.
Because the patient’s blasts can easily be identified
using HLA antibodies, the method will also allow the
64 R. Handgretinger et al.Figure 5. Flowcytometric analysis of peripheral blood chimerism posttransplant. In this example, the donor (D) is HLA-A2/28 positive, whereas
the recipient (R) is HLA-A2/28 negative. At day1200 posttransplant, all NK cells (A) and T cells (B) are donor-derived. The HLA-A2/28 neg-
ative population stained positive for CD45dim, whereas all donor-derived hematopoietic cells were CD451 bright (C). Further analysis (D)
showed that most of the HLA-A2/28 negative cells were CD341 and had the same leukemic phenotype as the patient’s blasts prior to transplant.analysis of the interaction of the donor-derived NK
or T cells with the recipient-derived blasts by using
flowcytometric approaches for assays of cellular
cytotoxicity [28].
OUTLOOK
The very low rate of TRM and the absence of le-
thal infections after haploidentical transplantation us-
ing this RIC approach and CD3/CD19-depleted stem
cells in pediatric patients offers a platform for further
improving the outcome after transplantation. Espe-
cially in patients with malignant disease, further de-
tailed analysis of the TCR and the repertoire of KIR
and KAR receptors might help to better understand
and manipulate the donor-derived immune reconstitu-
tion toward a powerfull graft-versus-malignancy ef-
fect. Newly described methods using oligonucleotide
microarray technology for the detailed analysis of the
TCR [29] or novel approaches for the quantitative
analysis of the KIR and KAR expression of NK cells
(X. Chen et al., submitted) in combination with flow-
cytometric analysis of recipient- and donor-derived
effector cells will facilitate a better understanding of
the interaction of reconstituting T and NK cells withthe patients’ malignant cells. The further availability
of the donor after transplantation allows further
intervention, such as the transfer of donor-derived
virus-specific T cells [22] or purified NK cells in case
of impending relapse [30]. Using this platform, further
clinical studies using posttransplant strategies to
further improve immune reconstition with cytokines
[31,32] or to augment the antitumor effect with
monoclonal antibodies [33,34] or other strategies are
warranted.
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